D. Gien

发表

Heterogeneous molecular background of the weak C, VS+, hrB–, HrB– phenotype in black persons

A. Blancher, G. Juszczak, P. Rouger, 2009, Transfusion.

Molecular background of novel silent RHCE alleles

B. Wibaut, G. Juszczak, P. Rouger, 2013, Transfusion.

High immunogenicity of red blood cell antigens restricted to the population of African descent in a cohort of sickle cell disease patients

P. Bierling, R. Djoudi, F. Pirenne, 2018, Transfusion.

Identification of novel silent KEL alleles causing KEL:−5 (Ko) phenotype or discordance between KEL:1,−2 phenotype/KEL*01/02 genotype

B. Pham, D. Gien, P. Le Pennec, 2013, Transfusion.

Analysis of RhCE variants among 806 individuals in France: considerations for transfusion safety, with emphasis on patients with sickle cell disease

G. Juszczak, P. Rouger, B. Pham, 2011, Transfusion.

Antibodies to co‐trimoxazole (trimethoprim and/or sulfamethoxazole) related to the presence of the drug in a commercial low‐ionic‐strength solution

P. Pennec, P. Rouger, B. Pham, 2012, Transfusion.

Molecular analysis of patients with weak D and serologic analysis of those with anti-D (excluding type 1 and type 2)

B. Pham, D. Gien, P. Le Pennec, 2013, Immunohematology.

Anti‐D investigations in individuals expressing weak D Type 1 or weak D Type 2: allo‐ or autoantibodies?

P. Pennec, P. Rouger, B. Pham, 2011, Transfusion.

Anti‐D investigations in individuals expressing weak D Type 1 or weak D Type 2: allo‐ or autoantibodies?

P. Rouger, B. Pham, T. Peyrard, 2011, Transfusion.